Pure Global

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis - Trial NCT06332287

Access comprehensive clinical trial information for NCT06332287 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Province Nanjing Brain Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06332287
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT06332287
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis
A Prospective, Single-arm, and Exploratory Phase II Clinical Study of Trilaciclib Combined With Lateral Ventricular Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Study Focus

NSCLC

combination of Trilaciclib and Pemetrexed

Interventional

drug

Sponsor & Location

Jiangsu Province Nanjing Brain Hospital

Suzhou, China

Timeline & Enrollment

Phase 2

May 01, 2023

Jun 01, 2025

25 participants

Primary Outcome

Duration of severe neutropenia (DSN)

Summary

To observe the efficacy of Trilaciclib combined with lateral ventricular chemotherapy in the
 treatment of non-small cell lung cancer with leptomeningeal metastasisใ€‚

Data Source

ClinicalTrials.gov

NCT06332287

Non-Device Trial